You just read:

Positive Topline Results of Large Phase 3 Trial Show Eisai's Lenvatinib Meets Primary Endpoint in Unresectable Hepatocellular Carcinoma

News provided by

Eisai Inc.

25 Jan, 2017, 08:00 ET